ANI Pharmaceuticals (NASDAQ:ANIP) Director Sells $146,070.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Renee Tannenbaum sold 1,800 shares of the stock in a transaction on Friday, December 5th. The stock was sold at an average price of $81.15, for a total value of $146,070.00. Following the completion of the sale, the director owned 25,157 shares of the company’s stock, valued at $2,041,490.55. The trade was a 6.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

ANI Pharmaceuticals Price Performance

ANIP traded up $0.33 during trading on Tuesday, reaching $81.67. 232,431 shares of the company traded hands, compared to its average volume of 376,402. The company has a market cap of $1.84 billion, a P/E ratio of 50.10 and a beta of 0.48. The company has a debt-to-equity ratio of 1.20, a quick ratio of 2.04 and a current ratio of 2.58. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $99.50. The firm has a fifty day simple moving average of $88.29 and a 200 day simple moving average of $80.19.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.74 by $0.30. The firm had revenue of $227.81 million for the quarter, compared to analysts’ expectations of $211.92 million. ANI Pharmaceuticals had a return on equity of 26.73% and a net margin of 4.91%.The business’s revenue was up 53.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.34 earnings per share. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. On average, equities analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Institutional Trading of ANI Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ANIP. Global Alpha Capital Management Ltd. raised its position in shares of ANI Pharmaceuticals by 17.2% in the 2nd quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company’s stock valued at $56,251,000 after purchasing an additional 126,500 shares during the last quarter. UBS Group AG grew its position in ANI Pharmaceuticals by 45.8% during the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after purchasing an additional 185,172 shares during the last quarter. Aberdeen Group plc increased its stake in ANI Pharmaceuticals by 76.1% during the 1st quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company’s stock valued at $28,059,000 after purchasing an additional 181,134 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in shares of ANI Pharmaceuticals in the third quarter worth $32,992,000. Finally, Rubric Capital Management LP raised its holdings in shares of ANI Pharmaceuticals by 33.3% in the third quarter. Rubric Capital Management LP now owns 343,414 shares of the specialty pharmaceutical company’s stock worth $31,457,000 after buying an additional 85,745 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ANIP. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 16th. Guggenheim raised their target price on shares of ANI Pharmaceuticals from $114.00 to $115.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Weiss Ratings reiterated a “buy (b-)” rating on shares of ANI Pharmaceuticals in a report on Monday. Zacks Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 21st. Finally, Truist Financial upped their target price on ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $99.38.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.